BMY Bristol-Myers Squibb Company

52.79
+0.54  (+1%)
Previous Close 52.25
Open 51.11
Price To Book 2.31
Market Cap 119,435,440,405
Shares 2,262,463,353
Volume 14,495,242
Short Ratio 2.72
Av. Daily Volume 16,161,217
Stock charts supplied by TradingView

NewsSee all news

  1. Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease

    Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for ZEPOSIA® (ozanimod) for the treatment of

  2. New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia

    Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo Bristol-Myers Squibb Company (NYSE:BMY) and

  3. Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020

    Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2020 on Thursday, May 7, 2020. During a conference call at 8:30 a.m. ET on May 7, 2020, company executives will review financial

  4. U.S. Food and Drug Administration Approves Bristol Myers Squibb's ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

    In clinical trials, ZEPOSIA demonstrated efficacy on a key clinical marker of disease activity – annualized relapse rate (ARR) – as compared to AVONEX® (interferon beta-1a)1,2,3 ZEPOSIA is a sphingosine-1-phosphate

  5. New Directors Elected to BiondVax's Board of Directors

    JERUSALEM, March 24, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 1H 2021.
CM-649 – Opdivo+ Yervoy or Chemo
Gastric cancer
Phase 2 data April 25, 2019 did not meet primary endpoints.
CM-714 Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 1 data at ASH 2018 noted at lowest dose ORR 79%; CR 43%.
JCARH125 - EVOLVE
Multiple myeloma
Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate. Further data due 2020.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Late-breaker at SITC November 11, 2017. ORR 14-32%.
BMS-986205 and Nivolumab
Advanced tumors
Phase 1b initiated.
JCAR017 in combination with durvalumab - PLATFORM
Non-hodgkin Lymphoma
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrolment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Approval announced March 6, 2018.
Opdivo - 4 week applications
Approval announced November 10, 2017.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia
Approval announced July 6, 2017.
ORENCIA
Psoriatic Arthritis (PsA)
Phase 1/2 preliminary data presented at ASCO June 2, 2017. ORR=21%.
CM-358 – Opdivo
Cervical, vaginal and vulvar cancers
Phase 1/2 ORR rate of 12.5% noted at ASCO June 3, 2017.
BMS-986016 - LAG-3 + Opdivo
Melanoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
FDA Approval announced March 11, 2020.
Opdivo and Yervoy
Previously Treated Hepatocellular Carcinoma
Phase 2 data at ASH December 2019 noted primary endpoint met in 10%~32% of patients across four cohorts.
Luspatercept
Myelofibrosis
Phase 2 data due 2018.
TG4010 and Opdivo
Non-squamous non-small cell lung cancer (NSCLC)
Phase 2 late breaker at ASCO June 5, 2017. Control rate 44%. ORR 19%.
Opdivo + Yervoy
Malignant pleural mesothelioma (MPM)
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Approval announced August 1, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 first overall survival (OS) positive data released April 3, 2017
CM - 067 Opdivo in combination with Yervoy
Melanoma
Phase 3 data due 1H 2020.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Phase 3 data released January 19, 2017.
Opdivo - ONO-4538-12
Gastric cancer
Phase 2 presentation at AACR Meeting April 16, 2018.
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 enrollment complete - noted April 27, 2017.
REVLIMID - MM-026 ARUMM
Multiple Myeloma - Maintenance Post-VMP induction
Phase 3 data due 2020.
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
FDA Approval announced May 28, 2019.
REVLIMID - AUGMENT
Relapsed or Refractory Follicular Lymphoma
Phase 3 data due mid-2020.
Ozanimod - TRUE NORTH
Ulcerative Colitis
PDUFA date April 4, 2020. Advisory Committee meeting originally set for December 18, 2019 is no longer required - noted December 6, 2019.
Luspatercept
Myelodysplastic syndromes (MDS) cancer
Phase 3 trial met primary endpoint - September 12, 2019. Median OS HR 0.69.
Oral Azacitidine - CC-486-AML-001
AML Maintenance
Phase 3 data due est 2020.
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 data released June 2017 - met the endpoint of a pre-planned interim futility analysis.
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
FDA Approval announced March 26, 2020.
ZEPOSIA (Ozanimod)
Relapsing Multiple Sclerosis
Approved February 22, 2017.
REVLIMID
Multiple myeloma (MM) - autologous stem cell transplant (ASCT)
Phase 3 data due 1H 2021.
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 trial did not meet primary endpoint - June 24, 2019.
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 ongoing.
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 trial did not meet primary endpoint - November 26, 2018.
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 data released October 12, 2018 - primary endpoint not met.
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 interim data released June 6, 2017 - primary endpoint met. Data presented at ESMO September 10, 2017 - HR 0.65 compared to Yervoy. FDA Approval announced December 20, 2017.
CM-238 – Opdivo (Adjuvant)
Melanoma
Approved April 16, 2018.
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
PDUFA date under priority review May 15, 2020.
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3 trial met primary endpoint - November 30, 2017.
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Urothelial Carcinoma - Bladder cancer
Opdivo (nivolumab)
Bladder cancer
BLA filing due 1H 2020.
ide-cel bb2121 - KarMMa
Relapsed/refractory multiple myeloma
PDUFA date under priority review August 17, 2020.
liso-cel (JCAR017) - TRANSCEND NHL-001
Relapsed or refractory (R/R) large B-cell lymphoma
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 data due released Feb 17, 2017 - primary endpoint met, disability endpoint not met. Full data released October 27, 2017 at ECTRIMS meeting.
Ozanimod - SUNBEAM
Relapsing Multiple Sclerosis
Approval announced July 11, 2018.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 data due 2021+.
Ozanimod
Crohn's disease
FDA approval announced August 17, 2018.
CM-32 - Opdivo+chemo
Small cell lung cancer (SCLC)
Phase 1 updated data at ASH December 8, 2019. 45.5% CR; 81.5% ORR.
Liso-cel (JCAR017) - TRANSCEND CLL-004
Chronic Lymphocytic Leukemia (CLL)
Phase 3 clinical hold lifted June 1, 2018.
CM-602 – Opdivo + pomalidomide and dexamethasone
Multiple Myeloma
FDA approval announced November 6, 2018.
Empliciti (elotuzumab) - ELOQUENT-3
Relapsed/refractory multiple myeloma
FDA Approval announced January 2, 2019.
Sprycel (dasatinib)
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1 data at ASH December 9, 2019 - 83% complete response.
bb21217
Multiple Myeloma
Phase 2 data due mid-2021.
IPI-549 + Nivolumab (MARIO-275)
Urothelial cancer
FDA Approval announced March 8, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 3 data due 2H 2020.
CM-648 Opdivo + Yervoy
Esophageal Cancer
Phase 3 data due 2H 2021
CM-901 Opdivo + Yervoy
Urothelial Cancer
Phase 3 data due 2H 2020.
CM-274 Opdivo (nivolumab)
Bladder cancer
Phase 3 data due 2021.
CM-577 - Opdivo
Esophageal cancer
Phase 3 primary completion date 1H 2021.
CM-743 Opdivo + Yervoy
Mesothelioma
Phase 3 data did not meet co-primary endpoint of recurrence-free survival (RFS). Trial to continue to assess RFS in the all-comer (intent-to-treat) endpoint. Data 2H 2020.
Opdivo (nivolumab) and Ipilimumab (Yervoy) CM-915
Melanoma
Phase 3 trial did not meet PFS endpoint. Trial to continue to allow OS endpoint to mature - September 5, 2019. Data due 2021.
CM-548 - Opdivo
First-line Glioblastoma (GBM) cancer
Phase 3 data due 2022.
CM-914 Opdivo in combination with Yervoy
Renal Cell Carcinoma
Phase 3 interim data met primary endpoint at interim analysis - October 22, 2019.
CM-9LA Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data released May 9, 2019 did not meet primary endpoint.
CM-498 Opdivo
Phase 3 data due 2H 2019.
Phase 2 trial initiated 4Q 2018.
liso-cel (JCAR017) - TRANSCEND OUTREACH
Relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL)
FDA Approval announced August 16, 2019.
Fedratinib
Myelofibrosis
Phase 3 data due 2022.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma
sNDA to be filed 2020.
POMALYST (pomalidomide)
Kaposi’s sarcoma
FDA Approval announced November 8, 2019.
Luspatercept
Beta-thalassemia
Phase 2 presentation at EHA June 15, 2019.
ADCETRIS and Opdivo CM-744
Relapsed/Refractory Classical Hodgkin Lymphoma
Phase 2/3 data due 2H 2020.
Relatlimab and Nivolumab
Melanoma
Phase 3 data due 2H 2020.
Nivolumab Plus Ipilimumab (CM 816)
Non-Small Cell Lung Cancer (NSCLC)
Phase 1b ORR 19% (cabozantinib and nivolumab) /29% (cabozantinib, nivolumab and ipilimumab) - January 24, 2020.
Cabozantinib /nivolumab and ipilimumab (CM-040)
Hepatocellular cancer
Phase 3 trial did not meet progression-free survival primary endpoint - March 9, 2020.
Lenalidomide and Dexamethasone and Elotuzumab (ELOQUENT - 1)
Multiple Myeloma

Latest News

  1. Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease

    Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for ZEPOSIA® (ozanimod) for the treatment of

  2. New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia

    Results demonstrate that treatment with Reblozyl provides significant reduction in transfusion burden for patients with beta thalassemia-associated anemia compared to placebo Bristol-Myers Squibb Company (NYSE:BMY) and

  3. Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020

    Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2020 on Thursday, May 7, 2020. During a conference call at 8:30 a.m. ET on May 7, 2020, company executives will review financial

  4. U.S. Food and Drug Administration Approves Bristol Myers Squibb's ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

    In clinical trials, ZEPOSIA demonstrated efficacy on a key clinical marker of disease activity – annualized relapse rate (ARR) – as compared to AVONEX® (interferon beta-1a)1,2,3 ZEPOSIA is a sphingosine-1-phosphate

  5. New Directors Elected to BiondVax's Board of Directors

    JERUSALEM, March 24, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the

  6. S&P 500 buybacks up 3.2% in Q4 2019; Full Year 2019 down 9.6% from record 2018, as companies brace for a more volatile 2020

    NEW YORK, March 24, 2020 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2019 S&P 500® stock buybacks, or share repurchases, were $181.6 billion – a 3.2% increase

  7. Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors

    Industry Leader Joins Vasomune's Board of Directors as the Company Transitions to Clinical Development of AV-001 for the Treatment of COVID-19/pathogen-induced ARDS Vasomune Therapeutics, Inc., an early stage

  8. Bristol-Myers Squibb Postpones April 2, 2020 Investor Day

    Bristol-Myers Squibb Company (NYSE:BMY) today announced that due to the ongoing COVID-19 pandemic, it will reschedule its planned April 2, 2020 Investor Day for a later date. The company will continue to assess the

  9. Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development

    Bristol Myers Squibb Company (NYSE:BMY) announced today that Elizabeth Mily has been appointed Executive Vice President, Strategy & Business Development, effective March 30, 2020. In this role, Mily will oversee

  10. Kitov Closes $6.0 Million Public Offering

    TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today

  11. Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast

    Company's marketing partners in the U.S. plan to commence selling Consensi in May 2020Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through 2022 TEL AVIV,

  12. Kitov Announces Pricing of $6.0 Million Public Offering

    TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  13. U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib

    Opdivo + Yervoy is the first and only dual immunotherapy approved in this setting Approval based on CheckMate -040 trial in which Opdivo + Yervoy showed an overall response rate of 33% (16/49; 95% CI: 20-48) in this

  14. Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma

    Phase 3 trial did not meet primary endpoint of progression-free survival in patients not eligible for transplant Bristol Myers Squibb Company (NYSE:BMY) today announced topline results from ELOQUENT-1, a Phase 3,

  15. Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

    Regulatory News: Voluntis (Paris:VTX) ((Euronext Paris, TSX:VTX), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a collaboration agreement to create and investigate

  16. Bristol‑Myers Squibb Announces Dividend Increase

    The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty-five cents ($0.45) per share on the $.10 par value Common Stock of the corporation. The next quarterly

  17. GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

    TAMPA, FL / ACCESSWIRE / February 26, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™)

  18. Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers

    Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer

  19. Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer

    First approval of Opdivo for treatment of advanced esophageal cancer First Immuno-Oncology treatment option approved for patients with esophageal cancer in Japan Bristol-Myers Squibb Company (NYSE:BMY) today

  20. Bristol-Myers Squibb to Hold Investor Day on April 2

    Bristol-Myers Squibb Company (NYSE:BMY) today announced that it will hold an Investor Day in New York City on Thursday, April 2, 2020. Giovanni Caforio, M.D., chairman and chief executive officer, and members of the

  21. Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma

    Bristol-Myers Squibb Company (NYSE:BMY) today announced five-year follow-up results from the Phase 3 CheckMate -025 study, which continue to demonstrate that treatment with Opdivo (nivolumab) delivers superior overall

  22. Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    Updated results from CheckMate -214 study show that more than 50% of patients treated with Opdivo plus Yervoy were alive at 42 months compared to 39% of patients treated with sunitinib Complete response rates, per

  23. Multinational Inflammatory Bowel Disease Survey Uncovers Striking Differences in Patients' and Physicians' Treatment Goals and Disease Management Expectations

    Survey reveals important differences in how patients and physicians define disease remission and the importance of remission as a clinical goal1 The high prevalence of corticosteroid therapy currently in use in IBD

  24. U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb's Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma

    U.S. FDA set a target action date of August 17, 2020 Application based on results from the TRANSCEND NHL 001 trial, the largest study of CD19-directed CAR T cells to support a BLA to date Liso-cel is a CD19-directed

  25. Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results

    TEL AVIV, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  26. Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019

    Reports Fourth Quarter Revenues of $7.9 Billion; $26.1 Billion for Full Year Posts Fourth Quarter GAAP Loss Per Share of $0.55 and Non-GAAP EPS of $1.22 Completes Acquisition of Celgene; Integration and Synergy

  27. BioMotiv and Bristol-Myers Squibb Announce the Launch of Anteros Pharmaceuticals

    BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into therapeutics, and

  28. Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24

    Patent Provides Coverage Until 2035 and Strengthens Company's IP Portfolio TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing

  29. Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

    U.S. application for Opdivo and Yervoy in first-line NSCLC based on CheckMate -227 study under review with PDUFA date of May 15, 2020 Company committed to first-line lung cancer patients in Europe, U.S. and other

  30. FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb

    Boehringer Ingelheim initiates Phase 1 clinical trial for SOS1:KRAS inhibitor BI 1701963, a FORMA-discovered, BI-licensed protein-protein interaction program for patients with advanced, KRAS-mutated solid tumors

  31. Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

    TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  32. U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer

    Application based on results from Part 1 of Phase 3 CheckMate -227 study Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics

  33. Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)

    Nektar Therapeutics (NASDAQ:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into

  34. Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer

    TEL AVIV, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  35. New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial

    Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today

  36. Kitov Pharma Announces Closing of FameWave Acquisition

    Concurrent with the close of the transaction, OrbiMed, Pontifax and Arkin are investing $3.5 million in Kitov and will each hold approximately 11% of the company's shares on a non-diluted basisAcquisition strengthens

  37. Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule

    TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  38. Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy

    Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and packaging

  39. Evotec And Bristol-Myers Squibb Expand iPSC Collaboration

    ADDING CELL TYPES SUPPORTS DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES AND TRIGGERS US$ 6 M PAYMENT TO EVOTECHAMBURG, GERMANY / ACCESSWIRE / January 7, 2020 / Evotec SE ((Frankfurt Stock

  40. Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Bristol-Myers Squibb Company (NYSE:BMY) will present at the J.P. Morgan 38th Annual Healthcare Conference on Monday, January 13, 2020 in San Francisco. Giovanni Caforio, chairman and chief executive officer, will make a

  41. Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference

    Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference on Thursday, January 9, 2020 in New York. Giovanni Caforio, M.D., chairman

  42. Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma

    Revlimid plus rituximab is the first chemotherapy-free combination regimen approved in Europe for patients with follicular lymphoma who have relapsed or did not respond to previous treatment Approval was based on

  43. WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer

    BALTIMORE and PHILADELPHIA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to evaluate the

  44. Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020

    Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2019 on Thursday, February 6, 2020. During a conference call at 8:30 a.m. ET on February 6, 2020, company executives will review

  45. Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA

    BLA submission includes data from TRANSCEND NHL 001 trial evaluating liso-cel in patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma Bristol-Myers Squibb Company

  46. Bristol-Myers Squibb Announces Leadership Changes

    Kathryn Metcalfe Appointed Executive Vice President, Corporate Affairs Tim Power Appointed Vice President and Head of Investor Relations John Elicker to Retire in March 2020 Bristol-Myers Squibb Company

  47. Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001

    Maintenance treatment with CC-486 resulted in a significant improvement in overall survival compared with placebo for front-line AML patients CC-486 had a manageable safety profile Data presented at the 2019

  48. bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

    Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 bluebird bio, Inc. (NASDAQ:BLUE) and

  49. Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting

    Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called

  50. Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting

    Heavily pre-treated patients with chronic lymphocytic leukemia receiving liso-cel achieved durable complete responses, including undetectable minimal residual disease Preliminary data from the PILOT study showed

  51. Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer

    Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting

  52. Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study

    Data from the pivotal liso-cel TRANSCEND NHL 001 study demonstrate patients with relapsed/refractory large B-cell lymphomas experienced high rate of durable responses Generally manageable safety profile with low

  53. Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

    Study met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population Safety results are consistent with the data presented

  54. Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)

    Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug

  55. Bristol-Myers Squibb Announces Dividend Increase

    The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 9.8% percent in the company's quarterly dividend, beginning in the first quarter of 2020. The dividend increase will

  56. Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant

      Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA® (abatacept) for the prevention of moderate to severe

  57. Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes

    Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers

  58. Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights

    Bristol-Myers Squibb Company (NYSE:BMY) will hold an investor webcast on Sunday, December 8, 2019 at 8:00 p.m. ET to discuss data presented at the American Society of Hematology meeting, in Orlando. Company executives

  59. Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the final results of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene Corporation

  60. Amgen Completes Acquisition Of Otezla® (apremilast)

    THOUSAND OAKS, Calif., Nov. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for

  61. Celgene Announces Plans to Transfer Listing of Celgene's Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb

    Celgene Corporation (NASDAQ:CELG) announced today that following the completion of Celgene's acquisition by Bristol-Myers Squibb Company (NYSE:BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of

  62. Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company

    Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by

  63. Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%

    Bristol-Myers Squibb Company (NYSE:BMY) today announced results for one of the co-primary endpoints from CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo

  64. Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE:NOW) will replace Celgene in the S&P 500 prior to

  65. Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today that it currently expects there will be no further extension of the expiration date of the offers to exchange (the "Exchange Offers")

  66. Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

    Company Has Now Satisfied All Regulatory Approvals for Celgene Acquisition Transaction Expected to Close on November 20, 2019 FTC Approves Agreement between Celgene and Amgen to Divest OTEZLA® Bristol-Myers Squibb

  67. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  68. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  69. U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma

    The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has

  70. Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting1

    Remission maintenance and structural damage inhibition findings from the Phase IIIb AVERT-2 study highlight potential role for ORENCIA in de-escalation regimens in early moderate-to-severe rheumatoid arthritis (RA)

  71. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  72. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  73. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  74. Bristol-Myers Squibb Reports Third Quarter Financial Results

    Increases Third Quarter Revenues 6% to $6.0 Billion Posts Third Quarter GAAP EPS of $0.83 and Non-GAAP EPS of $1.17 Announces CheckMate -9LA Meets Primary Endpoint of Overall Survival Presents Important New Data

  75. Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference

    Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Wolfe Research Healthcare Conference on Wednesday, November 6, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive

  76. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  77. Bristol-Myers Squibb Awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT

    Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life sciences and biotech startups, today announced that Carmine Therapeutics and STIMIT are the

  78. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  79. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  80. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  81. European Commission Approves Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection

    Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused

  82. CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer

    Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer Bristol-Myers Squibb Company

  83. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  84. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  85. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  86. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  87. Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.S

    In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royaltiesCoeptis Pharmaceuticals has engaged a distribution partner with an established sales

  88. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  89. Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board

    Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company

  90. Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer

    Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels Median duration of response for patients treated with Opdivo

  91. Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

    52% of patients treated with Opdivo plus Yervoy were alive at five years 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free Results represent longest follow-up to

  92. Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients

     Three-year analysis from Phase 3 CheckMate -238 study represents longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting Bristol-Myers Squibb Company (NYSE:BMY) today announced results of a three-year

  93. Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have...

    Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or

  94. Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene

  95. Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights

    Bristol-Myers Squibb Company (NYSE:BMY) will host a webcast on Saturday, September 28, 2019 at 7:30 p.m. CEST (1:30 p.m. EDT) to discuss data presented at the European Society of Medical Oncology, in Barcelona, Spain.

  96. Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers

    Overall survival data from CheckMate -227 Part 1 evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in advanced non-small cell lung cancer featured in ESMO Presidential Symposium Five-year survival data

  97. Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019

    Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2019 on Thursday, October 31, 2019. During a conference call at 8:30 a.m. ET on October 31, company executives will review financial

  98. Bristol-Myers Squibb Board Announces Election of Three New Directors

    Mr. Michael Bonney, Dr. Julia A. Haller and Ms. Phyllis Yale to Join BMS Board as Independent Directors

  99. Bristol‑Myers Squibb Announces Dividend

    The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.41) per share on the $.10 par value Common Stock of the corporation. The next quarterly

  100. Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients

    Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated a greater than five-fold increase in five-year overall survival rates; 13.4% for

  101. Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance

    Data validates NT-219 mechanism of action in reversing resistance to various FDA-approved treatments in pancreatic tumor models of mice implanted with biopsies from patients (PDX) NT-219's novel mechanism

  102. Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

    Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the

  103. More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research

     10-year cancer survivor Dana Vaughns joins colleagues in cross-country cycling relay with a goal to raise more than $1 million for the V Foundation for Cancer Research Bristol-Myers Squibb Company (NYSE:BMY) employee

  104. BioMotiv and Bristol-Myers Squibb Form Strategic Partnership

    BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a new strategic

  105. Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference

    Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will

  106. Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference

    TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  107. European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

    Median progression-free survival and overall response rate doubled among patients receiving EPd compared to pomalidomide and low-dose dexamethasone alone Second Empliciti-based combination approved in Europe for

  108. Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology

    SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ multiplexed intratumoral microdosing platform, today announced